Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

NEW YORK, Dec. 16 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients.

The trial, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib (Velcade®) and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib" is a double-blind, placebo-controlled trial comparing the efficacy and safety of perifosine vs. placebo when combined with bortezomib (Velcade®) and dexamethasone. The trial will enroll approximately 400 patients with relapsed or relapsed / refractory multiple myeloma. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety. This trial is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA). Additionally, the FDA has granted perifosine Orphan Drug and Fast Track designations in this indication.

The Phase 3 trial is being led by the Principal Investigator, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, at Dana-Farber Cancer Institute (DFCI) in Boston, MA and Dr. Kenneth C, Anderson, Chief, Division of Hematologic Neoplasia at DFCI. An estimated 40 to 50 centers throughout the United States and select centers outside of the United States will be participating in this Phase 3 trial.

Dr. Richardson's clinical research focuses on studying novel therapies for multiple myeloma. He was the lead investigator of the

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Calif. , Aug. 21, 2014 Asterias ... the emerging field of regenerative medicine, announced today the ... to the Company,s newly expanded Board of Directors. With ... eight directors, three of whom are independent. ... experience working with emerging growth companies. He is currently ...
(Date:8/20/2014)... Aug. 20, 2014 Northstar Global Business ... after months of hard work from many talented ... Snorenz formulation and package design.  The new formulation ... back into the product due to overwhelming evidence ... effects.  Snorenz Nighttime will also include these vitamins, ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kentucky blocked the sale of more ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical,company, ... the role of SPARC (secreted protein acidic ... Abraxis' nanoparticle,albumin-bound (nab(TM)) tumor-targeting technology at the ... Meeting held,April 14-18, 2007 in Los Angeles., ...
... 19, 2007 /PRNewswire-FirstCall/ --,CuraGen Corporation and TopoTarget ... on intravenous belinostat,(PXD101), a histone deacetylase (HDAC) ... are expected to be presented at two,upcoming ... one poster presentation discussing interim clinical,results with ...
Cached Medicine Technology:Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5
(Date:8/21/2014)... August 22, 2014 Top10BestSEOHosting.com has ... announces that iPage ( http://www.top10bestseohosting.com/go/iPage/ ) is one ... 2014. , The manager of Top10BestSEOHosting.com states, ... hosting supplier. Actually, these companies have outperformed their ... customer support. People can get the best web ...
(Date:8/21/2014)... August 21, 2014 Living in a ... atmosphere that comes along with it. A quality Home ... that such amenities are available. , ... Fayetteville, Georgia and Community Association Management, LLC made a ... Parks Company to provide an additional amenity for their ...
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... Dallas, TX (PRWEB) August 21, 2014 ... August 20 entertained residents with dementia at Silverado Turtle ... Improv Troupe, which consists of entertainers ranging from ages ... each time they perform their 40-minute set. The troupe's ... makes it universal and allows them to touch audiences ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
Breaking Medicine News(10 mins):Health News:iPage Reviews Unveiled Online At Top10BestSEOHosting.com 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 3Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4
... ... , ... March 31, 2010 -- Thanks to the Oscar-winning movie Slumdog Millionaire, the desperate living ... world attention. No one seems to escape except the miraculous but fictional star of ...
... ... recognized the nonprofit Tostan for its innovative work in bringing about positive, scalable community-led ... ... the Skoll Foundation named nonprofit Tostan as a 2010 recipient ...
... Kingdom are reporting evidence that consumption of insects contaminated ... the mysterious global decline of meat-eating, or carnivorous, plants. ... adverse effects on the plants. It appears in ACS, ... Iain Green and Christopher Moody note that many ...
... paradox for Passover and year-round: With observant Jews numbering barely ... why are 40-50 percent of food items on supermarket shelves ... growing popularity of kosher foods appear in an article in ... C&EN Senior Editor Bethany Halford notes that the ...
... to more careful cancer screening , WEDNESDAY, March 31 (HealthDay ... can be improved if doctors use a simple form, a ... percent and 17 percent of breast cancers. That,s why a ... health. But because of time constraints, many primary-care doctors don,t ...
... The HLP and ... Taking a proactive stance with respect to data management and search terms - as well ... ... Integration (“HLP”) and Pat Taylor and Associates, Inc. (“PTA”) are pleased to announce a project ...
Cached Medicine News:Health News:Slumdog Millionaire Put Spotlight on Slums in Developing World Now, Health Visionary Helps Turn Urban Blight into Hope 2Health News:Slumdog Millionaire Put Spotlight on Slums in Developing World Now, Health Visionary Helps Turn Urban Blight into Hope 3Health News:Tostan and Molly Melching Receive 2010 Skoll Award for Social Entrepreneurship 2Health News:Tostan and Molly Melching Receive 2010 Skoll Award for Social Entrepreneurship 3Health News:Tostan and Molly Melching Receive 2010 Skoll Award for Social Entrepreneurship 4Health News:Simple Forms Help Docs Do Better Breast Exams 2Health News:HLP Integration and Pat Taylor and Associates, Inc. Announce a Project Alliance. 2
Serrated rake tip spatula with 20 gauge shaft. Black finish for reduced glare. Can be used with 20 gauge MVR blades....
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Smooth, blunt round spatula for manipulations of the corneal flap. Ideal for placement under the flap to expose the stromal interface....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Medicine Products: